GlobeNewswire Inc.··Not SpecifiedAicuris Wins FDA Priority Review for First HSV Treatment in 20+ Years
Aicuris receives FDA Priority Review for pritelivir, a novel herpes simplex virus treatment. Phase 3 data shows 82.4% healing rate; PDUFA decision expected Q4 2026.
AHKSYPhase 3 trialPDUFA